ADCs, mAbs, CAR Ts: One Bioluminescent Platform Measures Them All
The HiBiT Target Cell Killing (TCK) platform, with off-the-shelf, mix-and-match components, measures four killing mechanisms for broad immunotherapy modality assessment. The post ADCs, mAbs, CAR Ts: One Bioluminescent Platform Measures Them All appeared first on GEN - Genetic Engineering and Biotechnology News .
The Promega HiBiT Target Cell Killing (TCK) platform is a bioluminescent cell-based system designed to measure cytotoxicity with specificity, simplicity, and sensitivity during immunotherapy development. The platform supports the assessment of four killing mechanisms—CAR-T cell-mediated killing, antibody-dependent cellular cytotoxicity (ADCC), T cell-dependent cellular cytotoxicity (TDCC), and antibody-dependent cellular phagocytosis (ADCP).
The HiBiT TCK platform leverages gain, not loss, of signal detection, which avoids kinetic complications of loss-of-signal assays and produces robust signal-to-noise with minimal cell numbers. The platform includes a growing library of off-the-shelf assay components, including functionally tested cell lines for blood cancer targets and solid tumor targets. Custom tailored target cells can also be created using ViaScript mRNA transfection.
Brief written by urgent.news from GEN Biotechnology's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
